| Tradename: | Joenja |
| Dailymedid: | Leniolisib |
| Routes Of Administration: | By mouth |
| Class: | Antineoplastic |
| Atc Prefix: | L03 |
| Atc Suffix: | AX22 |
| Legal Us: | Rx-only |
| Index2 Label: | as salt |
| Cas Number: | 1354690-24-6 |
| Cas Number2: | 1354691-97-6 |
| Drugbank: | DB16217 |
| Chemspiderid: | 52083264 |
| Unii: | L22772Z9CP |
| Kegg: | D11158 |
| Kegg2: | D11159 |
| Chembl: | 3643413 |
| Pdb Ligand: | 9NQ |
| Synonyms: | CDZ173 |
| C: | 21 |
| H: | 25 |
| F: | 3 |
| N: | 6 |
| O: | 2 |
| Smiles: | CCC(=O)N1CC[C@@H](C1)NC1=C2CN(CCC2=NC=N1)C1=CN=C(OC)C(=C1)C(F)(F)F |
| Stdinchi: | 1S/C21H25F3N6O2/c1-3-18(31)30-6-4-13(10-30)28-19-15-11-29(7-5-17(15)26-12-27-19)14-8-16(21(22,23)24)20(32-2)25-9-14/h8-9,12-13H,3-7,10-11H2,1-2H3,(H,26,27,28)/t13-/m0/s1 |
| Stdinchikey: | MWKYMZXCGYXLPL-ZDUSSCGKSA-N |
Leniolisib (INN[1] [2]), sold under the brand name Joenja, is a medication used for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS). It is a kinase inhibitor[3] that is taken by mouth.
The most common side effects include headache, sinusitis, and atopic dermatitis.
Leniolisib was approved for medical use in the United States in March 2023.[4] [5] [6] It is the first approved medication for the treatment of activated PI3K delta syndrome. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7]
Leniolisib is indicated for the treatment of activated phosphoinositide 3-kinase delta syndrome (activated PI3K delta syndrome) in people twelve years of age and older.
Activated PI3K delta syndrome is caused by mutations in either of two genes, PIK3CD or PIK3R1, that regulate the maturation of white blood cells, especially B cells and T cells. This leads to a decrease in immune cells, which makes it difficult for people with activated PI3K delta syndrome to fight off bacterial and viral infections.
Leniolisib is a selective phosphoinositide 3-kinase inhibitor (PI3Kδ inhibitor), which means it blocks a form of the protein called phosphoinositide 3-kinase delta (PI3Kδ) that is overactive in activated PI3K delta syndrome. By inhibiting PI3Kδ, leniolisib helps normalize immune function as measured by a significant increase in number of immune response generating B cells and reduction in size of lymph nodes.
The most common encountered adverse effects were headache, sinusitis, and atopic dermatitis.[8]
Leniolisib was developed by Novartis and subsequently licensed to Pharming Group, a Dutch biotechnology company, in 2019.
The US Food and Drug Administration (FDA) evaluated the efficacy of leniolisib in the placebo-controlled portion of Study 2201 (NCT02435173), a twelve‑week blinded, randomized, placebo-controlled study of 31 participants twelve years of age and older with confirmed APDS-associated genetic PI3Kδ mutation, with a documented variant in either PIK3CD or PIK3R1.
The FDA granted the application for leniolisib orphan drug, priority review, and rare pediatric disease designations.